The application relates to new substituted xanthines of general formula
wherein R
1
and R
2
are defined as in claims
1
to
11
, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
该申请涉及一般式的新取代
黄嘌呤,其中R1和R2如权利要求1至11中定义的,其互变异构体、对映体、非对映体、其混合物及其盐,具有有价值的药理特性,特别是对酶二肽基肽酶-IV(
DPP-IV)的抑制作用。